Glaukos (NYSE:GKOS) Director Sells $1,915,650.00 in Stock

Glaukos Corporation (NYSE:GKOS) Director Marc Stapley sold 15,000 shares of Glaukos stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $127.71, for a total value of $1,915,650.00. Following the sale, the director owned 37,449 shares in the company, valued at $4,782,611.79. This represents a 28.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Trading Up 4.5%

GKOS opened at $124.04 on Thursday. The firm’s fifty day moving average price is $112.34 and its 200 day moving average price is $96.59. The stock has a market capitalization of $7.12 billion, a PE ratio of -80.55 and a beta of 0.67. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $161.78. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same quarter in the prior year, the business posted ($0.28) EPS. The company’s revenue for the quarter was up 38.1% on a year-over-year basis. As a group, research analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: FDA approval for iDose TR re‑administration — The U.S. FDA cleared an NDA supplement allowing re‑administration of the company’s sustained‑release glaucoma implant (iDose® TR). The label update expands the product’s clinical utility and supports recurring revenue potential from repeat treatments. Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose TR
• Positive Sentiment: Analyst price‑target lift at BTIG — BTIG raised its price target to $131 and maintained a buy rating, signaling incremental analyst conviction and providing upside to the current trading level. This contributed to positive investor sentiment. GKOS price target raised by BTIG
• Positive Sentiment: Analyst consensus remains constructive — Market and research reports show a consensus rating around “Moderate Buy” with an average target near $131, reflecting broad analyst support that can sustain buying interest. Glaukos Given Consensus Rating of “Moderate Buy” by Analysts
• Neutral Sentiment: Analyst views and institutional ownership are mixed — Coverage includes multiple buy ratings and a few sell calls; institutional ownership is high, which can amplify moves but also reduce volatility if positions are long‑term. MarketBeat GKOS analyst/ownership summary
• Negative Sentiment: Insider sales by senior executives — COO Joseph Gilliam sold 10,498 shares (disclosed) and director/executive Marc Stapley also sold shares recently. Insider selling can be perceived as a negative signal even if sales are for diversification or tax reasons. Insider selling details
• Negative Sentiment: Company still posts negative EPS and margins — Despite revenue growth, Glaukos remains unprofitable on a GAAP basis, a reminder that valuation and long‑term execution risk remain for investors. GKOS company financial snapshot

Institutional Investors Weigh In On Glaukos

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in shares of Glaukos by 2.6% in the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after buying an additional 198 shares during the period. Jones Financial Companies Lllp boosted its stake in Glaukos by 1,405.9% during the 1st quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 2,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Glaukos by 41.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock worth $22,636,000 after purchasing an additional 67,668 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Glaukos by 56.0% during the second quarter. GAMMA Investing LLC now owns 2,109 shares of the medical instruments supplier’s stock worth $218,000 after acquiring an additional 757 shares in the last quarter. Finally, Fifth Third Bancorp lifted its holdings in shares of Glaukos by 391.0% during the 2nd quarter. Fifth Third Bancorp now owns 4,453 shares of the medical instruments supplier’s stock valued at $460,000 after purchasing an additional 3,546 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Truist Financial boosted their price target on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, December 18th. UBS Group upped their target price on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, January 22nd. Stephens increased their target price on shares of Glaukos from $115.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 2nd. Finally, Wells Fargo & Company upped their target price on Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $132.54.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.